JP2016539089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539089A5 JP2016539089A5 JP2016521774A JP2016521774A JP2016539089A5 JP 2016539089 A5 JP2016539089 A5 JP 2016539089A5 JP 2016521774 A JP2016521774 A JP 2016521774A JP 2016521774 A JP2016521774 A JP 2016521774A JP 2016539089 A5 JP2016539089 A5 JP 2016539089A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- disease
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889421P | 2013-10-10 | 2013-10-10 | |
| US61/889,421 | 2013-10-10 | ||
| PCT/US2014/060129 WO2015054628A1 (en) | 2013-10-10 | 2014-10-10 | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019035055A Division JP2019108359A (ja) | 2013-10-10 | 2019-02-28 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539089A JP2016539089A (ja) | 2016-12-15 |
| JP2016539089A5 true JP2016539089A5 (https=) | 2017-11-24 |
| JP6760840B2 JP6760840B2 (ja) | 2020-09-23 |
Family
ID=52809873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521774A Active JP6760840B2 (ja) | 2013-10-10 | 2014-10-10 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
| JP2019035055A Pending JP2019108359A (ja) | 2013-10-10 | 2019-02-28 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019035055A Pending JP2019108359A (ja) | 2013-10-10 | 2019-02-28 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9512224B2 (https=) |
| EP (1) | EP3054976B1 (https=) |
| JP (2) | JP6760840B2 (https=) |
| KR (1) | KR102366682B1 (https=) |
| CN (1) | CN105848679A (https=) |
| AU (1) | AU2014331683B2 (https=) |
| BR (1) | BR112016008010A2 (https=) |
| CA (1) | CA2926944C (https=) |
| DK (1) | DK3054976T3 (https=) |
| EA (1) | EA037551B1 (https=) |
| ES (1) | ES2821814T3 (https=) |
| IL (1) | IL244976B (https=) |
| MX (1) | MX385575B (https=) |
| NZ (1) | NZ630881A (https=) |
| PT (1) | PT3054976T (https=) |
| SG (1) | SG11201602807PA (https=) |
| WO (1) | WO2015054628A1 (https=) |
| ZA (1) | ZA201602577B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| CN106474559B (zh) * | 2016-11-30 | 2019-07-12 | 西南交通大学 | 一种在心血管植入材料表面构建Sema 4D/Heparin微环境的方法 |
| CN110325213A (zh) * | 2017-02-22 | 2019-10-11 | 瓦西尼斯公司 | 神经退行性或神经炎性疾病中胶质细胞活化的早期检测 |
| CN106983919B (zh) * | 2017-03-06 | 2019-07-12 | 西南交通大学 | 一种Sema 4D-VEGF涂层的构建方法及应用 |
| WO2018204895A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| CN108499220B (zh) * | 2018-04-25 | 2020-07-31 | 山东纯江环境科技有限公司 | 石墨烯/聚丙烯非织造布过滤网制备方法及其应用 |
| CN110643635A (zh) * | 2018-10-22 | 2020-01-03 | 华中科技大学同济医学院附属协和医院 | Sema4D/PlexinB1信号通路基因沉默的应用 |
| JP7743447B2 (ja) * | 2020-06-19 | 2025-09-24 | ザ ジェネラル ホスピタル コーポレイション | 近赤外自己蛍光イメージングシステム及び方法 |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| KR102847091B1 (ko) * | 2022-08-25 | 2025-08-21 | 부산대학교 산학협력단 | 혈관석회화 동반 만성신부전에서 세마포린 4d의 용도 |
| CN116949097B (zh) * | 2023-09-20 | 2023-12-12 | 江苏集萃药康生物科技股份有限公司 | 一种sema4d人源化小鼠模型的构建方法及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| AU2002329540A1 (en) | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| EP1773885B1 (en) | 2004-08-05 | 2010-04-21 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| US20090181035A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| NZ604464A (en) | 2010-06-14 | 2014-03-28 | Vaccinex Inc | Anti-vegf antibodies and uses thereof |
| KR102003571B1 (ko) | 2011-05-13 | 2019-07-24 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 골형성 촉진제 |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
-
2014
- 2014-09-11 NZ NZ630881A patent/NZ630881A/en unknown
- 2014-10-10 EP EP14853023.1A patent/EP3054976B1/en active Active
- 2014-10-10 PT PT148530231T patent/PT3054976T/pt unknown
- 2014-10-10 JP JP2016521774A patent/JP6760840B2/ja active Active
- 2014-10-10 MX MX2016004551A patent/MX385575B/es unknown
- 2014-10-10 WO PCT/US2014/060129 patent/WO2015054628A1/en not_active Ceased
- 2014-10-10 ES ES14853023T patent/ES2821814T3/es active Active
- 2014-10-10 CN CN201480067853.5A patent/CN105848679A/zh active Pending
- 2014-10-10 CA CA2926944A patent/CA2926944C/en active Active
- 2014-10-10 US US14/511,679 patent/US9512224B2/en active Active
- 2014-10-10 KR KR1020167012123A patent/KR102366682B1/ko active Active
- 2014-10-10 SG SG11201602807PA patent/SG11201602807PA/en unknown
- 2014-10-10 AU AU2014331683A patent/AU2014331683B2/en active Active
- 2014-10-10 DK DK14853023.1T patent/DK3054976T3/da active
- 2014-10-10 BR BR112016008010A patent/BR112016008010A2/pt not_active Application Discontinuation
- 2014-10-10 EA EA201690728A patent/EA037551B1/ru unknown
-
2016
- 2016-04-07 IL IL244976A patent/IL244976B/en active IP Right Grant
- 2016-04-15 ZA ZA201602577A patent/ZA201602577B/en unknown
-
2019
- 2019-02-28 JP JP2019035055A patent/JP2019108359A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539089A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| JP2015212281A5 (https=) | ||
| JP2019059786A5 (https=) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2009518005A5 (https=) | ||
| JP2017528476A5 (https=) | ||
| JP2010500371A5 (https=) | ||
| JP2011518125A5 (https=) | ||
| JP2013198490A5 (https=) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2019504032A5 (https=) | ||
| JP2013539454A5 (https=) | ||
| JP2016183160A5 (https=) | ||
| JP2010535205A5 (https=) | ||
| JP2014502955A5 (https=) | ||
| JP2016063812A5 (https=) | ||
| JP2015504421A5 (https=) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2015514110A5 (https=) | ||
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| JP2011184466A5 (https=) | ||
| JP2014094951A5 (https=) | ||
| JP2014530215A5 (https=) | ||
| JP2011157378A5 (https=) |